EGFR+ Lung Cancer

Treatment with pembrolizumab demonstrated antitumor activity along with tolerable toxicity in patients with 4 different rare and hard-to-treat malignancies, according to results from a phase II study led by The University of Texas MD Anderson Cancer Center researchers and published in the Journal for ImmunoTherapy of Cancer.

The addition of tremelimumab to frontline durvalumab and the standard of care, platinum-based chemotherapy, did not demonstrate a statistically significant improvement in overall survival in patients with extensive-stage small cell lung cancer, missing the co-primary end point of the phase III CASPIAN trial, according to high-level results from the final analysis of the trial.

To help assess the advances the United States has made in decreasing cancer-related deaths, a collective of public health bodies found that monitoring trends in cancer risk, screening test use, and mortality is informative. A report published in&nbsp;<em>Cancer</em>&nbsp;shows that progress has been made in recent years, but there is more work to be&nbsp;<a>done.</a>

From 2001 to 2017, the cancer death rates continued to decline in the United States, and these decreases were observed in all major racial and ethnic groups, as well as in males, females, adolescents, young adults, and children. However, the rates of cancer incidence for all cancers slightly increased in females from 2012 to 2016, according to the Annual Report to the Nation on the Status of Cancer, which was published in&nbsp;Cancer.^&nbsp;

Zofia Piotrowska, MD, MHS, discusses the rationale for conducting the FLAURA trial in patients with&nbsp;<em>EGFR</em>-mutant non&ndash;small cell lung cancer and how the use of osimertinib impacted the treatment landscape for this patient population.

A post hoc analysis of the ALTER 0303 trial has found that anlotinib, compared with placebo, extended the time patients with advanced non-small cell lung cancer had before brain metastases developed or existing brain lesions increased in size, reports a recent paper in The Oncologist.

In an interview with&nbsp;Targeted Oncology, Tony S. K. Mok, MD, BMSc, FRCPC, discussed the final progression-free survival data for frontline alectinib comparted with crizotinib as treatment of patients with advanced&nbsp;ALK-positive non&ndash;small cell lung cancer in the ALEX trial.

The FDA granted Breakthrough Therapy designation to JNJ-61186372 for the treatment of patients with metastatic non-small cell lung cancer with&nbsp;EGFR&nbsp;exon 20 insertion mutation whose disease has progressed on or after platinum-based chemotherapy.

The FDA has accepted a Biologics License Application for MYL-1402O, a proposed biosimilar to bevacizumab, according to a press release from co-developers Biocon and Mylan. The BLA is seeking approval for the biosimilar as a treatment for multiple types of cancer and the FDA has set an action date goal of December 27, 2020, for a decision on the BLA.

As the new coronavirus disease 2019 creates problems internationally, health-wise and economically, it is also becoming a cause for concern throughout the oncology community.

Julie R. Brahmer, MD, discusses the role of molecular testing for patients with lung cancer and why this is particularly important for those with early-stage disease.

Changes in the tumor microenvironment following progression on EGFR tyrosine kinase inhibitor therapy suggest a potential for benefit from PD-1/PD-L1 inhibitors in patients with EGFR-positive non&ndash;small cell lung cancer, according to the results of a retrospective study published in Clinical Cancer Research.

In February 2020, the FDA gave indications to multiple therapies meant for treatment of solid tumor and hematologic malignancies. FDA action included 10 Priority Reviews, 2 Breakthrough Therapy designations, and 2 Fast Track designations.

A 60-Year Old Man With Untreated Stage IV EGFR-Mutated Non-Small Cell Lung Cancer

High volumes of mutations observed through liquid biopsies may be associated with an improvement in progression-free survival&nbsp; and clinical benefit after first-line standard-of-care pembrolizumab-based therapy in patients with metastatic non-small cell lung cancer, according to findings from a prospective biomarker trial conducted by investigators at the University of Pennsylvania Perelman School of Medicine and Abramson Cancer Center, which were published in&nbsp;Clinical Cancer Research.

In an interview with Targeted Oncology, Zofia Piotrowska, MD, MHS, discussed the role of EGFR inhibition as frontline treatment of patients with EGFR-mutant lung cancers, as well as the combinations with osimertinib that are currently underway and appearing promising for this treatment landscape.

The FDA Oncologic Drugs Advisory Committee agreed that ramucirumab plus erlotinib showed a favorable benefit/risk profile in patients with untreated metastatic EGFR-positive non&ndash;small cell lung cancer in the phase III RELAY study. The vote was 6 to 5 in favor of the combination and ODAC has scheduled a hearing to discuss the terms of the Biologic License Application.<br /> &nbsp;

In a <em>Targeted Oncology</em>&trade; case-based peer perspective live discussion, Sandip P. Patel, MD, associate professor of medicine at the University of California San Diego Health, discussed EGFR inhibition options for patients with non&ndash;small cell lung cancer, based on the case of a real patient.

A 62-Year-Old Male With Stage III Non-Small Cell Lung Cancer